The DOI matches its Crossref record; 299 of the 299 references it cites were found in a registry or an index.
Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency
Open accessAbstract
Tumor immunotherapy is only effective in a fraction of patients due to a low response rate and severe side effects, and these challenges of immunotherapy in clinics can be addressed through induction of immunogenic cell death (ICD). ICD is elicited from many antitumor therapies to release danger associated molecular patterns (DAMPs) and tumor‐associated antigens to facilitate maturation of dendritic cells (DCs) and infiltration of cytotoxic T lymphocytes (CTLs). The process can reverse the tumor immunosuppressive microenvironment to improve the sensitivity of immunotherapy. Nanostructure‐based drug delivery systems (NDDSs) are explored to induce ICD by incorporating therapeutic molecules for chemotherapy, photosensitizers (PSs) for photodynamic therapy (PDT), photothermal conversion agents for photothermal therapy (PTT), and radiosensitizers for radiotherapy (RT). These NDDSs can release loaded agents at a right dose in the right place at the right time, resulting in greater effectiveness and lower toxicity. Immunotherapeutic agents can also be combined with these NDDSs to achieve the synergic antitumor effect in a multi‐modality therapeutic approach. In this review, NDDSs are harnessed to load multiple agents to induce ICD by chemotherapy, PDT, PTT, and RT in combination of immunotherapy to promote the therapeutic effect and reduce side effects associated with cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhao, Y., Xiao, X., Zou, M., Ding, B., Xiao, H. J., Wang, M., Jiang, F., Cheng, Z., Ma, P., & Lin, J. (2020) · Advanced Materials · doi:10.1002/adma.202006363 · Cited by 50
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Clinical development and potential of photothermal and photodynamic therapies for cancer
Li, X., Lovell, J. F., Yoon, J., & Chen, X. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0410-2 · Cited by 3,456
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Nanoparticles in Photodynamic Therapy
Lucky, S. S., Soo, K. C., & Zhang, Y. (2015) · Chemical Reviews · doi:10.1021/cr5004198 · Cited by 2,980
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
Metal–Organic Framework (MOF)‐Based Drug/Cargo Delivery and Cancer Therapy
Wu, M., & Yang, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606134 · Cited by 2,285
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology
Tenzer, S., Docter, D., Kuharev, J., Musyanovych, A., Fetz, V., Hecht, R., Schlenk, F., Fischer, D., Kiouptsi, K., Reinhardt, C., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.181 · Cited by 2,283
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.009 · Cited by 1,791
Nanotechnology for Multimodal Synergistic Cancer Therapy
Fan, W., Yung, B., Huang, P., & Chen, X. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,791
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., et al. (2009) · Nature · doi:10.1038/nature08296 · Cited by 1,654
Endosomal escape pathways for delivery of biologicals
Varkouhi, A. K., Scholte, M., Storm, G., & Haisma, H. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.004 · Cited by 1,561
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Glycolysis inhibition for anticancer treatment
Pelicano, H., Martin, D. S., Xu, R.-H., & Huang, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209597 · Cited by 1,516
Mediating Tumor Targeting Efficiency of Nanoparticles Through Design
Perrault, S. D., Walkey, C., Jennings, T., Fischer, H. C., & Chan, W. C. W. (2009) · Nano Letters · doi:10.1021/nl900031y · Cited by 1,513
Biomimetic mineralization of metal-organic frameworks as protective coatings for biomacromolecules
Liang, K., Ricco, R., Doherty, C. M., Styles, M. J., Bell, S., Kirby, N., Mudie, S., Haylock, D., Hill, A. J., Doonan, C. J., et al. (2015) · Nature Communications · doi:10.1038/ncomms8240 · Cited by 1,496
Lysosomes as dynamic regulators of cell and organismal homeostasis
Ballabio, A., & Bonifacino, J. S. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0185-4 · Cited by 1,469
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Immunogenic cell stress and death
Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353
Ohta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334
Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities
Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R., & Tsourkas, A. (2012) · Science · doi:10.1126/science.1226338 · Cited by 1,322
IL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289
Using immunotherapy to boost the abscopal effect
Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260
Lysosomal acidification mechanisms
Mindell, J. A. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142317 · Cited by 1,258
Fever and the thermal regulation of immunity: the immune system feels the heat
Evans, S. S., Repasky, E. A., & Fisher, D. T. (2015) · Nature Reviews Immunology · doi:10.1038/nri3843 · Cited by 1,257
Glutathione metabolism in cancer progression and treatment resistance
Bansal, A., & Simon, M. C. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201804161 · Cited by 1,233
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Multifunctional sonosensitizers in sonodynamic cancer therapy
Son, S., Kim, J. H., Wang, X., Zhang, C., Yoon, S. A., Shin, J., Sharma, A., Lee, M. H., Cheng, L., Wu, J., et al. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00648f · Cited by 1,150
pH-Sensitive nano-systems for drug delivery in cancer therapy
Liu, J., Huang, Y., Kumar, A., Tan, A., Jin, S., Mozhi, A., & Liang, X.-J. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.11.009 · Cited by 1,121
Strategies to improve radiotherapy with targeted drugs
Begg, A. C., Stewart, F. A., & Vens, C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3007 · Cited by 1,118
Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
Sun, Q., Zhou, Z., Qiu, N., & Shen, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606628 · Cited by 1,058
Nanoparticle‐Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy
Duan, X., Chan, C., & Lin, W. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201804882 · Cited by 1,033
Minimal "Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles
Rodriguez, P. L., Harada, T., Christian, D. A., Pantano, D. A., Tsai, R. K., & Discher, D. E. (2013) · Science · doi:10.1126/science.1229568 · Cited by 985
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 952
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine
Donahue, N. D., Acar, H., & Wilhelm, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.04.008 · Cited by 944
Cancer nanomedicine for combination cancer immunotherapy
Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 940
Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers
Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj070 · Cited by 920
A STING-activating nanovaccine for cancer immunotherapy
Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 900
Self-citationThe roles of IFNγ in protection against tumor development and cancer immunoediting
Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00038-7 · Cited by 899
Kirkwood, J. M., Ibrahim, J. G., Sosman, J. A., Sondak, V. K., Agarwala, S. S., Ernstoff, M. S., & Rao, U. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2370 · Cited by 898
Inflammatory microenvironment remodelling by tumour cells after radiotherapy
McLaughlin, M., Patin, E. C., Pedersen, M., Wilkins, A., Dillon, M. T., Melcher, A. A., & Harrington, K. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0246-1 · Cited by 883
Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
The mechanism of HMGB1 secretion and release
Chen, R., Kang, R., & Tang, D. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00736-w · Cited by 849
Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death
Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Nam, J., Son, S., Ochyl, L. J., Kuai, R., Schwendeman, A., & Moon, J. J. (2018) · Nature Communications · doi:10.1038/s41467-018-03473-9 · Cited by 808
Fang, J., Islam, W., & Maeda, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.005 · Cited by 757
Cancer active targeting by nanoparticles: a comprehensive review of literature
Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1767-3 · Cited by 756
He, C., Duan, X., Guo, N., Chan, C., Poon, C., Weichselbaum, R. R., & Lin, W. (2016) · Nature Communications · doi:10.1038/ncomms12499 · Cited by 754
Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy
Li, H.-J., Du, J.-Z., Du, X.-J., Xu, C.-F., Sun, C.-Y., Wang, H.-X., Cao, Z.-T., Yang, X.-Z., Zhu, Y.-H., Nie, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522080113 · Cited by 724
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 682
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672
Lan, G., Ni, K., Xu, Z., Veroneau, S. S., Song, Y., & Lin, W. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b01072 · Cited by 662
Nanoparticle‐Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy
Chen, Q., Chen, J., Yang, Z., Xu, J., Xu, L., Liang, C., Han, X., & Liu, Z. (2019) · Advanced Materials · doi:10.1002/adma.201802228 · Cited by 661
Improving cancer immunotherapy through nanotechnology
Goldberg, M. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0186-9 · Cited by 628
Gong, N., Ma, X., Ye, X., Zhou, Q., Chen, X., Tan, X., Yao, S., Huo, S., Zhang, T., Chen, S., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0373-6 · Cited by 601
Self-citationLu, K., He, C., Guo, N., Chan, C., Ni, K., Lan, G., Tang, H., Pelizzari, C., Fu, Y.-X., Spiotto, M. T., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0203-4 · Cited by 596
Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
Vollmer, J., & Krieg, A. M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.12.008 · Cited by 585
Apetoh, L., Ghiringhelli, F., Tesniere, A., Criollo, A., Ortiz, C., Lidereau, R., Mariette, C., Chaput, N., Mira, J., Delaloge, S., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00573.x · Cited by 574
Wang, C., Xu, L., Liang, C., Xiang, J., Peng, R., & Liu, Z. (2014) · Advanced Materials · doi:10.1002/adma.201402996 · Cited by 566
Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
Alzeibak, R., Mishchenko, T. A., Shilyagina, N. Y., Balalaeva, I. V., Vedunova, M. V., & Krysko, D. V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001926 · Cited by 565
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M. J., Thomas, B., Rupar, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-246124 · Cited by 548
Targeting adenosine for cancer immunotherapy
Leone, R. D., & Emens, L. A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0360-8 · Cited by 543
Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525
Aptamer-based targeted therapy
Zhu, G., & Chen, X. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.08.005 · Cited by 522
MYC as a target for cancer treatment
Duffy, M. J., O'Grady, S., Tang, M., & Crown, J. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102154 · Cited by 514
Cytokines in Cancer Immunotherapy
Waldmann, T. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028472 · Cited by 507
Zhou, F., Feng, B., Yu, H., Wang, D., Wang, T., Ma, Y., Wang, S., & Li, Y. (2019) · Advanced Materials · doi:10.1002/adma.201805888 · Cited by 507
Lu, K., He, C., Guo, N., Chan, C., Ni, K., Weichselbaum, R. R., & Lin, W. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b06663 · Cited by 505
Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation
Garg, A. D., Nowis, D., Golab, J., Vandenabeele, P., Krysko, D. V., & Agostinis, P. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.003 · Cited by 496
Hatakeyama, H., Akita, H., & Harashima, H. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00059 · Cited by 495
Chao, Y., Xu, L., Liang, C., Feng, L., Xu, J., Dong, Z., Tian, L., Yi, X., Yang, K., & Liu, Z. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0262-6 · Cited by 493
Obeid, M., Panaretakis, T., Joza, N., Tufi, R., Tesniere, A., van Endert, P., Zitvogel, L., & Kroemer, G. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402201 · Cited by 474
Radiotherapy and Immunogenic Cell Death
Golden, E. B., & Apetoh, L. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.005 · Cited by 463
Duan, X., Chan, C., Guo, N., Han, W., Weichselbaum, R. R., & Lin, W. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b09538 · Cited by 458
Combining Nanomedicine and Immunotherapy
Shi, Y., & Lammers, T. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00148 · Cited by 457
Feng, B., Zhou, F., Hou, B., Wang, D., Wang, T., Fu, Y., Ma, Y., Yu, H., & Li, Y. (2018) · Advanced Materials · doi:10.1002/adma.201803001 · Cited by 451
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 450
Lu, J., Liu, X., Liao, Y.-P., Salazar, F., Sun, B., Jiang, W., Chang, C. H., Jiang, J., Wang, X., Wu, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01651-9 · Cited by 440
El-Sawy, H. S., Al-Abd, A. M., Ahmed, T. A., El-Say, K. M., & Torchilin, V. P. (2018) · ACS Nano · doi:10.1021/acsnano.8b06104 · Cited by 431
Enzyme responsive drug delivery systems in cancer treatment
Shahriari, M., Zahiri, M., Abnous, K., Taghdisi, S. M., Ramezani, M., & Alibolandi, M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.07.004 · Cited by 415
Semiconducting Polymer Nanomaterials as Near-Infrared Photoactivatable Protherapeutics for Cancer
Li, J., & Pu, K. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00569 · Cited by 412
Recent advances in nanomaterials for enhanced photothermal therapy of tumors
Hu, J.-J., Cheng, Y.-J., & Zhang, X.-Z. (2018) · Nanoscale · doi:10.1039/c8nr07627h · Cited by 409
Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered Nanoparticles
Arvizo, R. R., Miranda, O. R., Moyano, D. F., Walden, C. A., Giri, K., Bhattacharya, R., Robertson, J. D., Rotello, V. M., Reid, J. M., & Mukherjee, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024374 · Cited by 403
Photodynamic Efficiency: From Molecular Photochemistry to Cell Death
Bacellar, I., Tsubone, T., Pavani, C., & Baptista, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160920523 · Cited by 401
Song, G., Chen, Y., Liang, C., Yi, X., Liu, J., Sun, X., Shen, S., Yang, K., & Liu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201602111 · Cited by 394
Min, H., Wang, J., Qi, Y., Zhang, Y., Han, X., Xu, Y., Xu, J., Li, Y., Chen, L., Cheng, K., et al. (2019) · Advanced Materials · doi:10.1002/adma.201808200 · Cited by 394
Calreticulin: non‐endoplasmic reticulum functions in physiology and disease
Gold, L. I., Eggleton, P., Sweetwyne, M. T., Van Duyn, L. B., Greives, M. R., Naylor, S., Michalak, M., & Murphy‐Ullrich, J. E. (2010) · The FASEB Journal · doi:10.1096/fj.09-145482 · Cited by 382
Li, J., Zhen, X., Lyu, Y., Jiang, Y., Huang, J., & Pu, K. (2018) · ACS Nano · doi:10.1021/acsnano.8b04066 · Cited by 377
Recent Advances in Subcellular Targeted Cancer Therapy Based on Functional Materials
Chen, W., Luo, G., & Zhang, X. (2019) · Advanced Materials · doi:10.1002/adma.201802725 · Cited by 373
Targeted Charge‐Reversal Nanoparticles for Nuclear Drug Delivery
Xu, P., Van Kirk, E. A., Zhan, Y., Murdoch, W. J., Radosz, M., & Shen, Y. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200605254 · Cited by 370
Interleukin-2: Biology, Design and Application
Arenas-Ramirez, N., Woytschak, J., & Boyman, O. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.10.003 · Cited by 359
Zheng, P., Ding, B., Jiang, Z., Xu, W., Li, G., Ding, J., & Chen, X. (2021) · Nano Letters · doi:10.1021/acs.nanolett.0c04778 · Cited by 359
Zhu, L., Wang, T., Perche, F., Taigind, A., & Torchilin, V. P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304987110 · Cited by 358
Implications of the tumor immune microenvironment for staging and therapeutics
Taube, J. M., Galon, J., Sholl, L. M., Rodig, S. J., Cottrell, T. R., Giraldo, N. A., Baras, A. S., Patel, S. S., Anders, R. A., Rimm, D. L., et al. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.156 · Cited by 358
CD73: a potent suppressor of antitumor immune responses
Beavis, P. A., Stagg, J., Darcy, P. K., & Smyth, M. J. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.02.009 · Cited by 355
Ma, Y., Zhang, Y., Li, X., Zhao, Y., Li, M., Jiang, W., Tang, X., Dou, J., Lu, L., Wang, F., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b06040 · Cited by 355
Elimination of established tumors with nanodisc-based combination chemoimmunotherapy
Kuai, R., Yuan, W., Son, S., Nam, J., Xu, Y., Fan, Y., Schwendeman, A., & Moon, J. J. (2018) · Science Advances · doi:10.1126/sciadv.aao1736 · Cited by 352
Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice
Kim, J.-H., Kim, Y.-S., Park, K., Lee, S., Nam, H. Y., Min, K. H., Jo, H. G., Park, J. H., Choi, K., Jeong, S. Y., et al. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.014 · Cited by 350
Gas-Mediated Cancer Bioimaging and Therapy
Chen, L., Zhou, S.-F., Su, L., & Song, J. (2019) · ACS Nano · doi:10.1021/acsnano.9b04954 · Cited by 343
Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment
Chen, B., Dai, W., He, B., Zhang, H., Wang, X., Wang, Y., & Zhang, Q. (2017) · Theranostics · doi:10.7150/thno.16684 · Cited by 342
Self-citationIntracellular delivery of nanomaterials: How to catch endosomal escape in the act
Martens, T. F., Remaut, K., Demeester, J., De Smedt, S. C., & Braeckmans, K. (2014) · Nano Today · doi:10.1016/j.nantod.2014.04.011 · Cited by 340
Li, J., Yu, X., Jiang, Y., He, S., Zhang, Y., Luo, Y., & Pu, K. (2021) · Advanced Materials · doi:10.1002/adma.202003458 · Cited by 340
Barriers to drug delivery in solid tumors
Sriraman, S. K., Aryasomayajula, B., & Torchilin, V. P. (2014) · Tissue Barriers · doi:10.4161/tisb.29528 · Cited by 338
Ni, K., Lan, G., Chan, C., Quigley, B., Lu, K., Aung, T., Guo, N., La Riviere, P., Weichselbaum, R. R., & Lin, W. (2018) · Nature Communications · doi:10.1038/s41467-018-04703-w · Cited by 336
Acid-Active Cell-Penetrating Peptides for in Vivo Tumor-Targeted Drug Delivery
Jin, E., Zhang, B., Sun, X., Zhou, Z., Ma, X., Sun, Q., Tang, J., Shen, Y., Van Kirk, E., Murdoch, W. J., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja311180x · Cited by 329
Self-citationTrial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
Zhai, L., Spranger, S., Binder, D. C., Gritsina, G., Lauing, K. L., Giles, F. J., & Wainwright, D. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0420 · Cited by 322
Cytokines in immunogenic cell death: Applications for cancer immunotherapy
Showalter, A., Limaye, A., Oyer, J. L., Igarashi, R., Kittipatarin, C., Copik, A. J., & Khaled, A. R. (2017) · Cytokine · doi:10.1016/j.cyto.2017.05.024 · Cited by 319
Manipulating tumor hypoxia toward enhanced photodynamic therapy (PDT)
Dang, J., He, H., Chen, D., & Yin, L. (2017) · Biomaterials Science · doi:10.1039/c7bm00392g · Cited by 317
Song, W., Kuang, J., Li, C.-X., Zhang, M., Zheng, D., Zeng, X., Liu, C., & Zhang, X.-Z. (2018) · ACS Nano · doi:10.1021/acsnano.7b09112 · Cited by 314
Charge‐Reversal Drug Conjugate for Targeted Cancer Cell Nuclear Drug Delivery
Zhou, Z., Shen, Y., Tang, J., Fan, M., Van Kirk, E. A., Murdoch, W. J., & Radosz, M. (2009) · Advanced Functional Materials · doi:10.1002/adfm.200900825 · Cited by 311
Erythrocyte‐Inspired Delivery Systems
Hu, C. J., Fang, R. H., & Zhang, L. (2012) · Advanced Healthcare Materials · doi:10.1002/adhm.201200138 · Cited by 308
Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection
Zhang, J., Chen, C., Li, A., Jing, W., Sun, P., Huang, X., Liu, Y., Zhang, S., Du, W., Zhang, R., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00843-7 · Cited by 305
Brown, T. P., Bhattacharjee, P., Ramachandran, S., Sivaprakasam, S., Ristic, B., Sikder, M. O. F., & Ganapathy, V. (2020) · Oncogene · doi:10.1038/s41388-020-1216-5 · Cited by 304
Progress in Applications of Prussian Blue Nanoparticles in Biomedicine
Qin, Z., Li, Y., & Gu, N. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800347 · Cited by 301
Wang, M., Song, J., Zhou, F., Hoover, A. R., Murray, C., Zhou, B., Wang, L., Qu, J., & Chen, W. R. (2019) · Advanced Science · doi:10.1002/advs.201802157 · Cited by 294
Wang, C., Volotskova, O., Lu, K., Ahmad, M., Sun, C., Xing, L., & Lin, W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja500671h · Cited by 283
Could 3D models of cancer enhance drug screening?
Brancato, V., Oliveira, J. M., Correlo, V. M., Reis, R. L., & Kundu, S. C. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119744 · Cited by 281
MMP-Responsive ‘Smart’ Drug Delivery and Tumor Targeting
Yao, Q., Kou, L., Tu, Y., & Zhu, L. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.06.003 · Cited by 280
Influencing factors and strategies of enhancing nanoparticles into tumors in vivo
Zhang, M., Gao, S., Yang, D., Fang, Y., Lin, X., Jin, X., Liu, Y., Liu, X., Su, K., & Shi, K. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.033 · Cited by 274
Huang, Z., Wang, Y., Yao, D., Wu, J., Hu, Y., & Yuan, A. (2021) · Nature Communications · doi:10.1038/s41467-020-20243-8 · Cited by 272
Biofunctionalized targeted nanoparticles for therapeutic applications
Wang, A. Z., Gu, F., Zhang, L., Chan, J. M., Radovic-Moreno, A., Shaikh, M. R., & Farokhzad, O. C. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1063 · Cited by 270
Combined Magnetic Hyperthermia and Immune Therapy for Primary and Metastatic Tumor Treatments
Pan, J., Hu, P., Guo, Y., Hao, J., Ni, D., Xu, Y., Bao, Q., Yao, H., Wei, C., Wu, Q., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b08550 · Cited by 270
Zhao, X., Yang, K., Zhao, R., Ji, T., Wang, X., Yang, X., Zhang, Y., Cheng, K., Liu, S., Hao, J., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.032 · Cited by 256
Duan, X., Chan, C., Han, W., Guo, N., Weichselbaum, R. R., & Lin, W. (2019) · Nature Communications · doi:10.1038/s41467-019-09221-x · Cited by 256
Song, Q., Yin, Y., Shang, L., Wu, T., Zhang, D., Kong, M., Zhao, Y., He, Y., Tan, S., Guo, Y., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03186 · Cited by 254
Eikenes, L., Bruland, Ø. S., Brekken, C., & Davies, C. D. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1472 · Cited by 251
Sun, Y., Zhao, D., Wang, G., Wang, Y., Cao, L., Sun, J., Jiang, Q., & He, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.004 · Cited by 250
Yang, W., Zhang, F., Deng, H., Lin, L., Wang, S., Kang, F., Yu, G., Lau, J., Tian, R., Zhang, M., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b07212 · Cited by 248
Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy
Musetti, S., & Huang, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b05893 · Cited by 239
Photothermal Therapy Generates a Thermal Window of Immunogenic Cell Death in Neuroblastoma
Sweeney, E. E., Cano‐Mejia, J., & Fernandes, R. (2018) · Small · doi:10.1002/smll.201800678 · Cited by 238
Chao, Y., Liang, C., Tao, H., Du, Y., Wu, D., Dong, Z., Jin, Q., Chen, G., Xu, J., Xiao, Z., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz4204 · Cited by 237
In Situ Dendritic Cell Vaccine for Effective Cancer Immunotherapy
Yang, W., Zhu, G., Wang, S., Yu, G., Yang, Z., Lin, L., Zhou, Z., Liu, Y., Dai, Y., Zhang, F., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b08346 · Cited by 233
A Polymer Multicellular Nanoengager for Synergistic NIR‐II Photothermal Immunotherapy
Xu, C., Jiang, Y., Han, Y., Pu, K., & Zhang, R. (2021) · Advanced Materials · doi:10.1002/adma.202008061 · Cited by 233
Biomimetic Immuno‐Magnetosomes for High‐Performance Enrichment of Circulating Tumor Cells
Xiong, K., Wei, W., Jin, Y., Wang, S., Zhao, D., Wang, S., Gao, X., Qiao, C., Yue, H., Ma, G., et al. (2016) · Advanced Materials · doi:10.1002/adma.201601643 · Cited by 230
Recent advances in photonanomedicines for enhanced cancer photodynamic therapy
Hu, J.-J., Lei, Q., & Zhang, X.-Z. (2020) · Progress in Materials Science · doi:10.1016/j.pmatsci.2020.100685 · Cited by 228
Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy
Fan, Y., Kuai, R., Xu, Y., Ochyl, L. J., Irvine, D. J., & Moon, J. J. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03218 · Cited by 220
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma1
Carpentier, A., Laigle-Donadey, F., Zohar, S., Capelle, L., Behin, A., Tibi, A., Martin-Duverneuil, N., Sanson, M., Lacomblez, L., Taillibert, S., et al. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000475 · Cited by 212
CD73-Deficient Mice Are Resistant to Carcinogenesis
Stagg, J., Beavis, P. A., Divisekera, U., Liu, M. C. P., Möller, A., Darcy, P. K., & Smyth, M. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0420 · Cited by 211
Biological drug and drug delivery-mediated immunotherapy
Xiao, Q., Li, X., Li, Y., Wu, Z., Xu, C., Chen, Z., & He, W. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.018 · Cited by 211
Mei, H., Cai, S., Huang, D., Gao, H., Cao, J., & He, B. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.06.035 · Cited by 211
Luo, T., Ni, K., Culbert, A., Lan, G., Li, Z., Jiang, X., Kaufmann, M., & Lin, W. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c02129 · Cited by 210
Self-citationEngineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy
Gao, J., Wang, W.-Q., Pei, Q., Lord, M. S., & Yu, H.-J. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0400-z · Cited by 203
Liu, R., Hu, C., Yang, Y., Zhang, J., & Gao, H. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.09.001 · Cited by 200
Gao, A., Chen, B., Gao, J., Zhou, F., Saeed, M., Hou, B., Li, Y., & Yu, H. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04012 · Cited by 197
Wang, H., Tang, Y., Fang, Y., Zhang, M., Wang, H., He, Z., Wang, B., Xu, Q., & Huang, Y. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b00021 · Cited by 193
Recent advances of redox-responsive nanoplatforms for tumor theranostics
Chen, M., Liu, D., Liu, F., Wu, Y., Peng, X., & Song, F. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.030 · Cited by 191
Liu, W., Zou, M., Liu, T., Zeng, J., Li, X., Yu, W., Li, C., Ye, J., Song, W., Feng, J., et al. (2019) · Advanced Materials · doi:10.1002/adma.201900499 · Cited by 190
Yu, G., Rao, L., Wu, H., Yang, L., Bu, L., Deng, W., Wu, L., Nan, X., Zhang, W., Zhao, X., et al. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201801389 · Cited by 189
Yu, W., He, X., Yang, Z., Yang, X., Xiao, W., Liu, R., Xie, R., Qin, L., & Gao, H. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119309 · Cited by 189
Donlon, N. E., Power, R., Hayes, C., Reynolds, J. V., & Lysaght, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.045 · Cited by 189
Sun, F., Zhu, Q., Li, T., Saeed, M., Xu, Z., Zhong, F., Song, R., Huai, M., Zheng, M., Xie, C., et al. (2021) · Advanced Science · doi:10.1002/advs.202002746 · Cited by 188
Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.
Carpentier, A. F., Chen, L., Maltonti, F., & Delattre, J. (1999) · PubMed · Cited by 185
Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment
Liu, Z., Xiong, M., Gong, J., Zhang, Y., Bai, N., Luo, Y., Li, L., Wei, Y., Liu, Y., Tan, X., et al. (2014) · Nature Communications · doi:10.1038/ncomms5280 · Cited by 185
Liu, D., Chen, B., Mo, Y., Wang, Z., Qi, T., Zhang, Q., & Wang, Y. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b02306 · Cited by 185
Liu, H., Hu, Y., Sun, Y., Wan, C., Zhang, Z., Dai, X., Lin, Z., He, Q., Yang, Z., Huang, P., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b04181 · Cited by 185
Charge reversal nano-systems for tumor therapy
Zhang, P., Chen, D., Li, L., & Sun, K. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01221-8 · Cited by 178
Luo, L., Zhu, C., Yin, H., Jiang, M., Zhang, J., Qin, B., Luo, Z., Yuan, X., Yang, J., Li, W., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b00204 · Cited by 177
Rios-Doria, J., Durham, N., Wetzel, L., Rothstein, R., Chesebrough, J., Holoweckyj, N., Zhao, W., Leow, C. C., & Hollingsworth, R. (2015) · Neoplasia · doi:10.1016/j.neo.2015.08.004 · Cited by 174
Zhou, T., Liang, X., Wang, P., Hu, Y., Qi, Y., Jin, Y., Du, Y., Fang, C., & Tian, J. (2020) · ACS Nano · doi:10.1021/acsnano.0c01453 · Cited by 174
Mollazadeh, S., Mackiewicz, M., & Yazdimamaghani, M. (2021) · Materials Science and Engineering: C · doi:10.1016/j.msec.2020.111536 · Cited by 173
Nanomedicine‐Based Immunotherapy for the Treatment of Cancer Metastasis
Zhang, P., Zhai, Y., Cai, Y., Zhao, Y., & Li, Y. (2019) · Advanced Materials · doi:10.1002/adma.201904156 · Cited by 171
Carnovale, C., Bryant, G., Shukla, R., & Bansal, V. (2016) · Progress in Materials Science · doi:10.1016/j.pmatsci.2016.04.003 · Cited by 169
Bioresponsive polymeric nanotherapeutics for targeted cancer chemotherapy
Cheng, R., Meng, F., Deng, C., & Zhong, Z. (2015) · Nano Today · doi:10.1016/j.nantod.2015.09.005 · Cited by 165
Zheng, X., Wu, Y., Bi, J., Huang, Y., Cheng, Y., Li, Y., Wu, Y., Cao, G., & Tian, Z. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00786-6 · Cited by 163
Cheng, Y., Chen, Q., Guo, Z., Li, M., Yang, X., Wan, G., Chen, H., Zhang, Q., & Wang, Y. (2020) · ACS Nano · doi:10.1021/acsnano.0c05392 · Cited by 160
Zou, M., Liu, W., Li, C., Zheng, D., Zeng, J., Gao, F., Ye, J., & Zhang, X. (2018) · Small · doi:10.1002/smll.201801120 · Cited by 157
Hu, C., Lei, T., Wang, Y., Cao, J., Yang, X., Qin, L., Liu, R., Zhou, Y., Tong, F., Umeshappa, C. S., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120159 · Cited by 155
The progress and perspective of nanoparticle-enabled tumor metastasis treatment
Zhang, W., Wang, F., Hu, C., Zhou, Y., Gao, H., & Hu, J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.07.013 · Cited by 153
Cited by
Chiang, M.-R., Hsu, C.-W., Pan, W.-C., Tran, N.-T., Lee, Y.-S., Chiang, W.-H., Liu, Y.-C., Chen, Y.-W., Chiou, S.-H., & Hu, S.-H. (2025) · ACS Nano · doi:10.1021/acsnano.4c09525 · Cited by 174
Gong, J., Cheng, D., Liu, C., Wu, S., Sun, N., Zhao, L., Li, J., Xing, Y., & Zhao, J. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202404184 · Cited by 53
GSH/pH dual response drug delivery system for photothermal enhanced gene-immunotherapy
Ma, T., Li, W., Ye, J., Huang, C., Li, Y., Qiu, H., & Yin, S. (2023) · Nanoscale · doi:10.1039/d3nr03881e · Cited by 21
Wang, D., Lin, S., Li, T., Yang, X., Zhong, X., Chen, Q., Jiang, G., & Li, C. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101275 · Cited by 18
Metadata
- Authors
- Li, Z., Lai, X., Fu, S., Ren, L., Cai, H., Zhang, H., Gu, Z., Ma, X., & Luo, K.
- Venue
- Advanced Science
- Publisher
- Wiley
- Published
- 2022-06-02
- Volume
- 9
- Issue
- 22
- Pages
- e2201734-e2201734
- ISSN
- 2198-3844 (ISSN-L)
- OpenAlex
- W4281678632
- Cited by
- 680
- References
- 299
- FWCI
- 38.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.